KBC Group
INDV icon

KBC Group’s Indivior Pharmaceuticals INDV Stock Holding History

KBC Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Hold
75,831
– – 0.01% 591
2026
Q1 		$2.31M Buy
75,831
+72,523
+2,192% +$2.4M 0.01% 632
2025
Q4 		$119K Hold
3,308
– – ﹤0.01% 1177
2025
Q3 		$80K Buy
+3,308
New +$69.2K ﹤0.01% 1396

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's INDV Position: Q2 2026 in Review

KBC Group held its Indivior Pharmaceuticals (INDV) position steady in Q2 2026 at 75,831 shares worth $3.11M. The position accounts for 0.01% of the portfolio, ranked #591.

KBC Group first reported a position in INDV in Q3 2025 and has held it in 4 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • KBC Group held 75,831 shares of Indivior Pharmaceuticals worth $3.11M as of Q2 2026.
  • KBC Group left its Indivior Pharmaceuticals share count unchanged in Q2 2026.
  • Indivior Pharmaceuticals made up 0.01% of KBC Group's portfolio in Q2 2026, its #591 holding.
  • KBC Group first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.